淀粉样β正电子发射断层成像探针：批判性评价。
Amyloid-β positron emission tomography imaging probes: a critical review.
机构信息
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, CA 90095, USA.
出版信息
J Alzheimers Dis. 2013;36(4):613-31. doi: 10.3233/JAD-130485.
Abstract
The rapidly rising prevalence and cost of Alzheimer's disease in recent decades has made the imaging of amyloid-β deposits the focus of intense research. Several amyloid imaging probes with purported specificity for amyloid-β plaques are currently at various stages of FDA approval. However, a number of factors appear to preclude these probes from clinical utilization. As the available "amyloid specific" positron emission tomography imaging probes have failed to demonstrate diagnostic value and have shown limited utility for monitoring therapeutic interventions in humans, a debate on their significance has emerged. The aim of this review is to identify and discuss critically the scientific issues contributing to the extensive inconsistencies reported in the literature on their purported in vivo amyloid specificity and potential utilization in patients.
摘要
近年来，阿尔茨海默病的患病率和治疗费用迅速上升，使得淀粉样蛋白-β 沉积的成像成为研究的焦点。目前有几种据称对淀粉样蛋白-β 斑块具有特异性的淀粉样蛋白成像探针处于 FDA 批准的不同阶段。然而，有许多因素似乎使这些探针无法在临床上得到应用。由于现有的“淀粉样蛋白特异性”正电子发射断层扫描成像探针未能显示出诊断价值，并且在监测人类治疗干预方面的应用有限，因此对其意义的争论已经出现。本综述的目的是确定并批判性地讨论导致文献中报道的它们在体内淀粉样蛋白特异性和在患者中潜在应用的广泛不一致的科学问题。
相似文献
1
Amyloid-β positron emission tomography imaging probes: a critical review.淀粉样β正电子发射断层成像探针：批判性评价。
J Alzheimers Dis. 2013;36(4):613-31. doi: 10.3233/JAD-130485.
2
Technology Insight: imaging amyloid plaques in the living brain with positron emission tomography and MRI.技术洞察：利用正电子发射断层扫描和磁共振成像对活体大脑中的淀粉样斑块进行成像
Nat Clin Pract Neurol. 2005 Dec;1(2):96-105. doi: 10.1038/ncpneuro0046.
3
Development of positron-emission tomography/single-photon emission computed tomography imaging probes for in vivo detection of beta-amyloid plaques in Alzheimer's brains.用于体内检测阿尔茨海默病大脑中β-淀粉样蛋白斑块的正电子发射断层扫描/单光子发射计算机断层扫描成像探针的研发。
Chem Pharm Bull (Tokyo). 2009 Oct;57(10):1029-39. doi: 10.1248/cpb.57.1029.
4
[Amyloid-plaque imaging of the brain using PET].[使用正电子发射断层扫描（PET）对大脑进行淀粉样蛋白斑块成像]
Ned Tijdschr Geneeskd. 2011;155:A2981.
5
Compounds for imaging amyloid-β deposits in an Alzheimer's brain: a patent review.用于阿尔茨海默病大脑中淀粉样β沉积成像的化合物：专利审查。
Expert Opin Ther Pat. 2015 Apr;25(4):413-23. doi: 10.1517/13543776.2015.1007953. Epub 2015 Mar 8.
6
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.匹兹堡化合物 B 正电子发射断层扫描首位阿尔茨海默病患者的正电子发射断层扫描影像与分子病理学及临床进展的关系。
Brain. 2011 Jan;134(Pt 1):301-17. doi: 10.1093/brain/awq349. Epub 2010 Dec 13.
7
A copper radiopharmaceutical for diagnostic imaging of Alzheimer's disease: a bis(thiosemicarbazonato)copper(II) complex that binds to amyloid-beta plaques.一种用于诊断阿尔茨海默病的放射性铜药物：一种双（硫代氨基甲酸盐）铜（II）配合物，可与淀粉样β斑块结合。
Chem Commun (Camb). 2010 Aug 14;46(30):5437-9. doi: 10.1039/c0cc01175d. Epub 2010 Jun 17.
8
Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.氟代甲磺酸美他莫（18F）：一种用于阿尔茨海默病和痴呆症诊断的β淀粉样蛋白正电子发射断层显像剂。
Drugs Today (Barc). 2014 Mar;50(3):219-29. doi: 10.1358/dot.2014.50.3.2116672.
9
Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.氟代脱氧葡萄糖（18F）正电子发射断层扫描脑淀粉样蛋白：欧洲上市许可的重点。
Alzheimers Dement. 2014 Oct;10(5 Suppl):S395-9. doi: 10.1016/j.jalz.2013.09.007. Epub 2014 Jan 10.
10
[Amyloid PET imaging in patients with Alzheimer's disease].[阿尔茨海默病患者的淀粉样蛋白正电子发射断层显像]
Ned Tijdschr Geneeskd. 2017;161:D808.
引用本文的文献
1
Research trends of piezoelectric materials in neurodegenerative disease applications.压电材料在神经退行性疾病应用中的研究趋势
Bioact Mater. 2025 Jun 13;52:366-392. doi: 10.1016/j.bioactmat.2025.06.022. eCollection 2025 Oct.
2
Ligands for Protein Fibrils of Amyloid-β, α-Synuclein, and Tau.淀粉样β蛋白、α-突触核蛋白和tau蛋白原纤维的配体
Chem Rev. 2025 Jun 11;125(11):5282-5348. doi: 10.1021/acs.chemrev.4c00838. Epub 2025 May 6.
3
Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood-Brain Barrier Crossing Ability.有助于阿尔茨海默病诊断和治疗的纳米材料，解决血脑屏障穿透能力问题。
Adv Sci (Weinh). 2024 Oct;11(38):e2403473. doi: 10.1002/advs.202403473. Epub 2024 Aug 5.
4
Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?阿尔茨海默病淀粉样蛋白假说和抗体疗法：冰川消融？
Int J Mol Sci. 2024 Mar 31;25(7):3892. doi: 10.3390/ijms25073892.
5
FDG-PET versus Amyloid-PET Imaging for Diagnosis and Response Evaluation in Alzheimer's Disease: Benefits and Pitfalls.18F-氟脱氧葡萄糖正电子发射断层扫描（FDG-PET）与淀粉样蛋白正电子发射断层扫描（Amyloid-PET）在阿尔茨海默病诊断及疗效评估中的应用：优势与局限
Diagnostics (Basel). 2023 Jul 3;13(13):2254. doi: 10.3390/diagnostics13132254.
6
Discovery of High-Affinity Amyloid Ligands Using a Ligand-Based Virtual Screening Pipeline.基于配体的虚拟筛选管道发现高亲和力淀粉样蛋白配体。
J Am Chem Soc. 2023 Jul 26;145(29):15936-15950. doi: 10.1021/jacs.3c03749. Epub 2023 Jul 13.
7
Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials.淀粉样蛋白 PET：阿尔茨海默病免疫疗法试验中一个有争议的单一主要替代疗效指标。
J Alzheimers Dis. 2022;90(4):1395-1399. doi: 10.3233/JAD-220841.
8
The dense-core plaques of Alzheimer's disease are granulomas.阿尔茨海默病的致密核心斑块是肉芽肿。
J Exp Med. 2022 Aug 1;219(8). doi: 10.1084/jem.20212477. Epub 2022 Jun 22.
9
Lack of association between cortical amyloid deposition and glucose metabolism in early stage Alzheimer´s disease patients.早期阿尔茨海默病患者皮质淀粉样蛋白沉积与葡萄糖代谢之间缺乏关联。
Radiol Oncol. 2021 Dec 22;56(1):23-31. doi: 10.2478/raon-2021-0051.
10
11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous.11C-PiB PET 当棉绒斑较多时可能会低估脑内淀粉样蛋白-β负担。
Brain. 2022 Jun 30;145(6):2161-2176. doi: 10.1093/brain/awab434.
本文引用的文献
1
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.阿尔茨海默病病理生理过程的追踪：动态生物标志物的更新假设模型。
Lancet Neurol. 2013 Feb;12(2):207-16. doi: 10.1016/S1474-4422(12)70291-0.
2
2012 SNM Highlights Lectures.2012年核医学与分子影像学会亮点讲座
J Nucl Med. 2012 Sep;53(9):15N-31N.
3
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.γ-分泌酶抑制剂阿伐加司他在轻度至中度阿尔茨海默病2期研究中的安全性和耐受性
Arch Neurol. 2012 Nov;69(11):1430-40. doi: 10.1001/archneurol.2012.2194.
4
The toxicity of amyloid β oligomers.β-淀粉样蛋白寡聚体的毒性。
Int J Mol Sci. 2012;13(6):7303-7327. doi: 10.3390/ijms13067303. Epub 2012 Jun 13.
5
Predicting sites of new hemorrhage with amyloid imaging in cerebral amyloid angiopathy.利用淀粉样蛋白成像预测脑淀粉样血管病中的新出血部位。
Neurology. 2012 Jul 24;79(4):320-6. doi: 10.1212/WNL.0b013e31826043a9. Epub 2012 Jul 11.
6
The exception makes the rule: not all Aβ plaques are created equal.
Neurology. 2012 Jul 17;79(3):206-7. doi: 10.1212/WNL.0b013e31825fe11f. Epub 2012 Jun 13.
7
Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical Aβ deposition.亚急性缺血性卒中与局部 11C PiB 正电子发射断层扫描（PET）摄取相关，但与全脑新皮层 Aβ 沉积无关。
Stroke. 2012 May;43(5):1341-6. doi: 10.1161/STROKEAHA.111.636266. Epub 2012 Apr 5.
8
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.阿尔茨海默病神经病理变化与认知状态的相关性：文献综述。
J Neuropathol Exp Neurol. 2012 May;71(5):362-81. doi: 10.1097/NEN.0b013e31825018f7.
9
White matter hyperintensities predict amyloid increase in Alzheimer's disease.脑白质高信号预测阿尔茨海默病的淀粉样蛋白增加。
Neurobiol Aging. 2012 Dec;33(12):2766-73. doi: 10.1016/j.neurobiolaging.2012.01.016. Epub 2012 Mar 10.
10
Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease.11C-PiB 和 18F-氟比他滨在衰老和阿尔茨海默病中的 Aβ 成像比较。
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):983-9. doi: 10.1007/s00259-012-2088-x. Epub 2012 Mar 8.
Zotero 插件